ArticleMolecular diversity2026
From genome to drug targets: computational subtractive genomics reveals novel anti-filarial targets in Wuchereria bancrofti and identifies plant-based inhibitors of β-1,4-mannosyltransferase, a high-priority target.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphatic filariasis (LF) is a mosquito-transmitted parasitic disease, which is a main concern in tropical and subtropical countries. LF is the second major cause of chronic and irreversible disabilities worldwide, which include lymphoedema, hydrocele, and elephantiasis. According to the World Health Organization (WHO), an estimated 882 million individuals across 44 countries were reported to be at risk of acquiring LF. The nematode Wuchereria bancrofti is the predominant pathogen which causes LF, accounting for approximately 90% of filarial infections. The drugs albendazole (ALB), ivermectin (IVM), and diethylcarbamazine (DEC) are currently used to treat LF, but they are not effective against microfilariae and are known to have an inability to reverse chronic conditions, produce adverse reactions, and have developed drug resistance due to prolonged use. Further scientific studies are necessary to discover and characterize potential drug targets in the genome of W. bancrofti, which would facilitate the development of novel therapeutic approaches. This study employs a subtractive genomics approach to identify potential anti-filarial drug targets from the genome of W. bancrofti. Our analysis revealed 12 targets of W. bancrofti, which were found to be involved in important metabolic pathways such as combating oxidative stress, amino acid and nucleotide metabolism, folate biosynthesis, and DNA repair. This article highlights the proposed drug targets and their potential role in the development of effective drugs against W. bancrofti. We also propose beta-1,4-mannosyltransferase (WbEGH), one among the 12 identified targets, as a priority target based on its sequence similarity with human proteins. Further, structure-based virtual screening identified five potent phytochemicals (IMPPAT ID: 9,896,047, 49,777,225, 13,888,122, 89,483-03-4, and 14,605,093) having a better affinity with WbEGH. Furthermore, experimental validation of these identified phytochemicals would lead towards an effective method for controlling Lymphatic Filariasis.
Indexed as
Identifiers
40500576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.